Interleukin-34 protects against sepsis in mice by regulating CXCL1/CCL2 immune response
Author(s) -
Jianjun Wang,
Feng Yang,
Yuanyuan Bu,
Jinghong Jia,
Aibin Cheng,
Jihua Zhao
Publication year - 2022
Publication title -
tropical journal of pharmaceutical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.209
H-Index - 36
eISSN - 1596-5996
pISSN - 1596-9827
DOI - 10.4314/tjpr.v20i3.12
Subject(s) - cxcl1 , chemokine , sepsis , ccl2 , medicine , lactate dehydrogenase , immune system , cytokine , endocrinology , immunology , pharmacology , chemistry , enzyme , biochemistry
Purpose: To study the protective effect of interleukin-34 (IL-34) against sepsis in mice, and the mechanism involved.
Methods: Ninety healthy male mice were selected and assigned to sham, model and recombinant IL-34 protein groups. The activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) were assayed. Moreover, histopathological changes in lung, liver and kidney were recorded, and levels of C-X-C Motif Chemokine Ligand 1 (CXCL1) and C-C Motif Chemokine Ligand 2 (CCL2) in each group of mice were measured.
Results: Peritoneal lavage fluid and serum concentrations of AST, ALT, LDH, CXCL1 and CCL2 were significantly elevated, relative to sham mice (p < 0.05). Mice survival in the drug group was markedly increased from day 1 to day 5; also, serum ALT, LDH and AST were significantly reduced, while CXCL1 and CCL2 concentrations in serum and peritoneal lavage fluid were increased, relative to model mice (p < 0.05).
Conclusion: IL-34 improves survival of septic mice by inducing CXCL1/CCL2 immune response, resulting in a protective effect on the airway. Thus, the CXCL1/CCL2 pathway mediated by IL-34 may be useful in the development of drugs for the treatment of sepsis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom